Finance

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Published by Global Banking & Finance Review

Posted on February 6, 2026

1 min read

· Last updated: February 6, 2026

Add as preferred source on Google
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Global Banking & Finance Awards 2026 — Call for Entries

Feb 6 (Reuters) - Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million. (Reporting by Prakhar Srivastava in Bengaluru;

Agomab Therapeutics Sees 8% Drop in Nasdaq Debut, Valued at $716 Million

Agomab Therapeutics Nasdaq Debut

Feb 6 (Reuters) - Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.

Initial Market Reaction

(Reporting by Prakhar Srivastava in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

  • Agomab Therapeutics shares fell 8% on Nasdaq debut.
  • The company is valued at $716.4 million post-debut.
  • Initial market reaction was negative.
  • Agomab is a Belgium-based biotech firm.
  • The debut was reported by Reuters.

Frequently Asked Questions

What is a Nasdaq debut?
A Nasdaq debut refers to the first day a company's shares are traded on the Nasdaq stock exchange, marking its entry into the public market.
What is market valuation?
Market valuation is the total value of a company's outstanding shares of stock, calculated by multiplying the share price by the total number of shares.
What is an equity investment?
An equity investment involves purchasing shares of a company, giving the investor ownership rights and a claim on a portion of the company's assets and earnings.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category